Gmür J P, Burger J, Schaffner A, Neftel K, Oelz O, Frey D, Metaxas M
Department of Internal Medicine, University Hospital, Zürich, Switzerland.
Blood. 1990 Jan 1;75(1):290-5.
In 3 of 15 consecutive patients receiving a human leukocyte antigen (HLA)-identical but major ABO incompatible bone marrow transplant (BMT), pure red cell aplasia (PRA) lasting 5 to 8 months was observed. Titers of the incompatible anti-A agglutinin before infusion of the red blood cell (RBC)-depleted BMT was very high in one, and in the usual range in two patients. Decrease of agglutinin titers during the first 4 weeks after BMT were comparable between PRA patients and those of ABO-incompatible BMT recipients with timely RBC recovery. However, in PRA patients, agglutinin titers rose again and remained elevated for 19 to 28 weeks. RBC engraftment and reticulocyte recovery ultimately occurred spontaneously and coincided with the decrease of agglutinin titers below 16. These observations indicate that PRA is antibody-dependent in this setting. Furthermore, it is conceivable that cyclosporine facilitates recipient-derived antibody synthesis after major ABO-incompatible BMT.
在15例连续接受人类白细胞抗原(HLA)匹配但ABO血型主要不相合的骨髓移植(BMT)的患者中,观察到3例出现了持续5至8个月的纯红细胞再生障碍性贫血(PRA)。在输注去除红细胞(RBC)的BMT前,1例患者不相合的抗A凝集素效价非常高,另外2例患者的效价在正常范围内。BMT后前4周,PRA患者与ABO血型不相合且红细胞及时恢复的BMT受者的凝集素效价下降情况相当。然而,PRA患者的凝集素效价再次升高并持续19至28周。红细胞最终自发植入,网织红细胞恢复,同时凝集素效价降至16以下。这些观察结果表明,在这种情况下,PRA是抗体依赖性的。此外,可以想象,环孢素会促进ABO血型主要不相合的BMT后受者来源的抗体合成。